Keywords: Pradaxa, Wararin, Stroke, Boehringer Ingelheim, Cost benefit, Prime Therapeutics
Benefits of Boehringer’s Pradaxa come at high cost, study finds
Article | 20 October 2011
Treating patients with the new blood thinning medication dabigatran (German independent drug major Boehringer Ingelheim’s recently approved Pradaxa), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
